In vivo, daily intraperitoneal administration of 5Z (2 mg/kg) from day 3 significantly ameliorated collagen antibody-induced arthritis (CAIA) in IFN-γ knock-out mice, highlighting its therapeutic potential.<h4>Conclusion</h4>TAK1 inhibition restores p53 functions in JIASFs and downregulates synovial inflammation, which warrants further studies that target TAK1 to treat JIA. The gene discussed is TP53; the disease is juvenile idiopathic arthritis.